Hydrophobic acrylic IOL corrects corneal astigmatism

Article

A new hydrophobic acrylic IOL is an effective, safe and predictable method for the correction of corneal astigmatism in patients undergoing routine cataract surgery.

A new hydrophobic acrylic IOL is an effective, safe and predictable method for the correction of corneal astigmatism in patients undergoing routine cataract surgery, according to recently published data.

Dr Amy L. Sheppard et al., School of Life and Health Sciences, Aston University, Birmingham, UK, completed a cohort study in four hospital eye clinics in Europe on 67 eyes of 60 patients.

The outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity, manifest refraction and keratometry. The team also documented individual patient satisfaction with uncorrected vision and the surgeon’s evaluation of ease of handling and performance of the IOL.

Four to eight weeks after cataract surgery, the mean UDVA was 0.15 logMAR ± 0.17 and UDVA was 20/40 or better in 88% of eyes. Mean refractive cylinder decreased significantly postoperatively from −1.91 ± 1.07 D to −0.67 ± 0.54 D. However, there was no change in keratometric cylinder. The good UDVA resulted in high levels of patient satisfaction.

The abstract for this study has been published in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.